Floatz logo

Survivin Peptide Vaccine

Carcinoma, Ductal

University of PennsylvaniavaccinePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Carcinoma, Ductal cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 2CCC
Docetaxel
Sanofi
Phase 2CCC
Inno-206
Sanofi
Phase 2CCC
EXEMESTANE
Dana-Farber Cancer Institute
Phase 2CCC
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2CCC

View all 10 →

Same molecule, other indications

Survivin Peptide Vaccine is also rated in:

anaplastic oligodendrogliomaDormant
CC
Indicative ·
47 / 100
View asset →
anaplastic oligoastrocytomaDormant
CC
Indicative ·
47 / 100
View asset →
giant cell glioblastomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →